Table 1. Demographic and Clinical Characteristics of Patients With Morphea by Main Subtype.
| Characteristic | Patients, No. (%) | P value | ||
|---|---|---|---|---|
| All (N = 944) | Morphea | |||
| Linear (n = 474) | Generalized (n = 244) | |||
| Age at onset, median (IQR), y | 16 (8-44) | 11 (6-18) | 52 (33-62) | <.001a |
| Sex | ||||
| Male | 203 (22) | 121 (26) | 40 (16) | .005b |
| Female | 741 (78) | 353 (74) | 204 (84) | |
| Race/ethnicity | ||||
| White | 723 (77) | 352 (74) | 192 (79) | .19b |
| Non-White | 221 (23) | 122 (26) | 52 (21) | |
| LoSCAT component, median (IQR)c | ||||
| mLoSSI | 4 (0-10) | 3 (0-6) | 13 (5-27) | <.001a |
| LoSDI | 9 (5-19) | 8 (5-14) | 19 (12-28) | <.001a |
| PGA-A | 20 (0-40) | 15 (0-40) | 30 (15-60) | <.001a |
| PGA-D | 30 (15-41) | 30 (20-50) | 20 (12-40) | <.001a |
| Patient-reported outcomes: DLQI and cDQLId | ||||
| Mild | 511 (54) | 263 (55) | 116 (48) | <.001b |
| Moderate | 155 (16) | 76 (16) | 53 (22) | |
| Severe | 135 (14) | 42 (9) | 50 (20) | |
| Clinical features and disease modifiers | ||||
| Deep involvemente | 367/703 (52) | 224/342 (65) | 76/222 (34) | <.001b |
| Superficial involvemente | 116/703 (17) | 34/342 (10) | 64/222 (29) | <.001b |
| Pansclerotic | 19 (2) | 0 | 16 (7) | <.001f |
| Erythema in lesion | 122 (13) | 61 (13) | 15 (6) | .006b |
| Dermal involvemente | 245/703 (35) | 111/342 (32) | 75/222 (34) | .74b |
| Hair loss in lesion | 122 (13) | 88 (19) | 27 (11) | .01b |
| Limited range of motion | 202 (21) | 123 (26) | 50 (20) | .11b |
| Joint deformity | 57 (6) | 40 (8) | 1 (0.4) | <.001f |
| Functional abnormality, by location | ||||
| Face/head/neck | 19 (2) | 12 (3) | 5 (2) | .69b |
| Trunk | 29 (3) | 18 (4) | 5 (2) | .21b |
| Extremity | ||||
| Lower | 147 (16) | 80 (17) | 40 (16) | .87b |
| Upper | 92 (10) | 43 (9) | 34 (14) | .046b |
Abbreviations: cDLQI, Child Dermatology Life Quality Index.; DLQI, Dermatology Life Quality Index; IQR, interquartile range; LoSCAT, Localized Scleroderma Cutaneous Assessment Tool; LoSDI, Localized Scleroderma Skin Damage Index; mLoSSI, modified Localized Scleroderma Skin Severity Index; PGA-A, Physician Global Assessment of Disease Activity; PGA-D, Physician Global Assessment of Disease Damage.
a
Computed with the Mann-Whitney test.
b
Computed with the χ2 test.
c
Data available for 734 of 944 patients.
d
Severity stratification: mild, 0 to 5; moderate, 6 to 10; and severe, 11 to 30.
e
Owing to discrepancies in data collection between the 2 databases, information available for 703 of 944 patients.
f
Computed with the Fisher exact test.